Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

947 - Modulation of Risk and Prognosis of Cutaneous Melanoma Patients by Genetic Polymorphisms on PDCD1 Gene

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Melanoma

Presenters

Gabriela Gomez

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

G.V.B. Gomez1, J.A. Rinck-Junior2, D.H.L. Da Silva3, R.L. Mamoni4, G.J. Lourenço1, A.M. Moraes1, C.S.P. Lima1

Author affiliations

  • 1 Department Of Internal Medicine, University of Campinas, 13083-888 - Campinas/BR
  • 2 Department Of Internal Medicine, University of Campinas, Campinas/BR
  • 3 Department Of Clinical Pathology, University of Campinas, Campinas, Campinas/BR
  • 4 Department Of Clinical Pathology, University of Campinas, Campinas, 13083-888 - Campinas/BR
More

Resources

Abstract 947

Background

This study aimed to evaluate whether PD1.1 (c.-606G>A), PD1 (c.627 + 252C>T), PD1.5 (c.804C>T) and PD1.9 (c.644C>T) single nucleotide polymorphisms (SNPs) on PDCD1 gene influence risk, clinicopathological aspects and survival of patients with cutaneous melanoma (CM).

Methods

We evaluated 250 CM patients diagnosed at the University of Campinas and 250 blood donors (controls). DNA was analyzed by real-time polymerase chain reaction (PCR) for genotyping. PDCD1 gene expression and PD1 protein expression were assessed by quantitative PCR and flow cytometry, respectively. The statistical significance of differences between groups was calculated using the Fisher's exact or chi-square test. Bonferroni method was used in multiple comparisons. PDCD1 expression and PD1 expression on T lymphocytes were calculated, using Kruskal-Wallis and Mann-Whitney test, respectively. The prognostic impact of SNPs on recurrence-free survival (RFS) and overall survival (OS) of CM patients were examined using the Kaplan Meier and Cox analyses.

Results

Individuals with PD1 CC genotype isolated and associated with PD1.5 CC genotype were under 2.20 (95% CI: 1.00-4.82, P= 0.04) and 2.51 (95% CI: 1.04-6.03, P= 0.03) times greater risks of developing CM, respectively. Individuals with phototype I or II and PD1 CC genotype or PD1 CC plus PD1.5 CC genotype had 5.89 and 6.71 more chances of presenting CM than others, respectively. PD1.5 TT genotype was associated with increased expression of PDCD1 gene when compared with CT or CC genotype (P= 0.03). PD1.5 CT or TT genotypes and T allele increased expression of PD1 protein in CD4+ lymphocytes (P= 0.01, P= 0.006; respectively). At 60 months of follow-up, shorter RFS was observed in patients with PD1.1 AA genotype (33.3% vs 72.5%, P= 0.02). Patients with PD1.1 AA genotype had 4.39 more chances of presenting tumor progression or relapse in univariate Cox analysis (P= 0.04) and patients with PD1.5 CC genotype had 2.38-fold increased risk of evolving to death in multivariate Cox analysis (P= 0.02).

Conclusions

The data suggest, for the first time, preliminary evidence that inherited abnormalities in regulation of T lymphocyte activities, related to PD1.1, PD1 and PD1.5 SNPs, alter CM risk and prognosis.

Clinical trial identification

Legal entity responsible for the study

Faculty of Medical Sciences, University of Campinas

Funding

São Paulo Research Foundation (FAPESP)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.